Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 431, 899-902 (21 October 2004) | doi:10.1038/431899a; Published online 20 October 2004
Antibiotics at the crossroads
Carl Nathan1
- Carl Nathan is in the Department of Microbiology & Immunology, Weill Cornell Medical College, and Programs in Immunology and Molecular Biology, Weill Graduate School of Medical Sciences of Cornell University, 1300 York Avenue, New York 10021, USA.
The public takes for granted that the pharmaceutical industry can anticipate society's medical needs and meet them. This faith is nowhere more evident than in the expectation that antibiotics are readily available to treat bacterial infections.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Antibiotic production from the ground upNature Biotechnology News and Views (01 Apr 2007)
Antibiotic production from the ground upNature Biotechnology News and Views (01 Apr 2007)